Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution [Seeking Alpha]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Seeking Alpha
OLMA is advancing palazestrant in late-stage trials for ER+/HER2- breast cancer, targeting both first-line and later-line settings, with pivotal readouts expected in 2025-2028. Despite strong momentum and sufficient funding, OLMA's valuation is driven by competitor data rather than its own, raising questions about risk and sustainability. Given the lengthy wait for Olema's key data and increased competition, I recommend a cautious approach and prefer gains based on Olema's own clinical results. kali9/E+ via Getty Images Investment Overview The share price of Olema Pharmaceuticals, Inc. OLMA ) jumped in value by 135% yesterday, as the San Francisco based, oncology focused biotech benefitted from the success of a rival. Swiss Pharma giant Roche ( More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the mar
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Olema Oncology to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Olema Pharmaceuticals (NASDAQ:OLMA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 12/1/25 - Form 4
- 11/25/25 - Form 4
- 11/19/25 - Form 8-K
- OLMA's page on the SEC website